ICON Public (NASDAQ:ICLR) PT Lowered to $285.00 at TD Cowen

ICON Public (NASDAQ:ICLR) had its price target decreased by TD Cowen from $369.00 to $285.00 in a research report report published on Friday morning, Benzinga reports. TD Cowen currently has a buy rating on the medical research company’s stock.

A number of other brokerages have also recently commented on ICLR. Truist Financial lowered their price target on ICON Public from $383.00 to $363.00 and set a “buy” rating for the company in a research note on Monday, October 14th. Robert W. Baird downgraded shares of ICON Public from an “outperform” rating to a “neutral” rating and set a $340.00 target price for the company. in a research note on Thursday. Barclays reduced their price target on shares of ICON Public from $330.00 to $275.00 and set an “overweight” rating on the stock in a research report on Friday. Baird R W cut shares of ICON Public from a “strong-buy” rating to a “hold” rating in a research report on Thursday. Finally, The Goldman Sachs Group reduced their target price on ICON Public from $370.00 to $280.00 and set a “buy” rating on the stock in a report on Friday. Four analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $310.45.

ICON Public Trading Down 0.6 %

Shares of NASDAQ ICLR opened at $220.47 on Friday. ICON Public has a fifty-two week low of $220.01 and a fifty-two week high of $347.72. The firm has a market capitalization of $18.19 billion, a P/E ratio of 25.70, a P/E/G ratio of 1.35 and a beta of 1.22. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.31 and a quick ratio of 1.31. The company’s 50 day simple moving average is $297.75 and its 200 day simple moving average is $310.18.

ICON Public (NASDAQ:ICLR) last posted its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). ICON Public had a net margin of 8.57% and a return on equity of 12.06%. The company had revenue of $2.03 billion during the quarter, compared to analyst estimates of $2.13 billion. During the same period last year, the company earned $3.10 EPS. The business’s revenue for the quarter was down 1.2% compared to the same quarter last year. On average, analysts predict that ICON Public will post 14.53 EPS for the current year.

Institutional Trading of ICON Public

A number of institutional investors have recently made changes to their positions in ICLR. Ashton Thomas Private Wealth LLC acquired a new position in shares of ICON Public during the 2nd quarter worth about $54,000. ORG Partners LLC acquired a new position in ICON Public during the second quarter valued at approximately $59,000. Whittier Trust Co. of Nevada Inc. grew its stake in ICON Public by 410.8% in the first quarter. Whittier Trust Co. of Nevada Inc. now owns 189 shares of the medical research company’s stock valued at $63,000 after purchasing an additional 152 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of ICON Public by 50.0% during the 2nd quarter. GAMMA Investing LLC now owns 261 shares of the medical research company’s stock worth $82,000 after purchasing an additional 87 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its holdings in shares of ICON Public by 17.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 283 shares of the medical research company’s stock valued at $95,000 after buying an additional 42 shares during the last quarter. Institutional investors own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.